The focus of our group is the development of new types of cell therapies approaches for neurodegenerative diseases.
Our group’s goal is to develop new therapeutic cell-based treatment approaches for neurodegenerative diseases by using adult stem cells or pluripotent stem cells such as human embryonic stem cells (hESCs) and induced human pluripotent stem cells (hiPSCs). Our aim is to develop clinically acceptable protocols for neural differentiation and to test them in different animal models as potential therapeutic tools to help treat spinal cord injuries and different types of ataxias. We also apply combinatorial approaches using small molecules in order to increase the success of cell-based therapies.
Hereditary retinal dystrophies are another subject of interest in our laboratory. In particular, we are focusing on creating new human cell models using patient-specific hiPSCs, and especially, retinal pigment epithelial (RPE) cells and optic-cup organoids derived from them. These can then be used to investigate the mechanisms driving these diseases, develop treatments, perform toxicity screens, and model development in cells affected by these diseases.
Using our expertise in obtaining and culturing these cell types, we were able to establish hiPSC cell lines from patients suffering from retinitis pigmentosa. Moreover, we intend to correct the faulty genes in these cells using Crispr/Cas9 technology and to optimize the derivation of RPE and photoreceptors from corrected hiPSCs as a cell source for transplantation therapies in animal models with retinal degeneration diseases. In collaboration with other laboratories, we are developing new tools for maintaining high cell viability while delivering RPE and photoreceptor cells into degenerated retina in small and large animal models.
Get to know us better
The people who make it all possible
Slaven Erceg Vukicevic
Francisco Rodríguez Jiménez
Ana Artero Castro
Maria Amp Pérez Arago
Nuria Martínez Alarcón
Our scientific contributions
Concise Review: Human Induced Pluripotent Stem Cell Models of Retinitis Pigmentosa
A. CASTRO, D. LUKOVIC, P. JENDELOVA and S. ERCEG
STEM CELLS, 2018 Apr,  Vol. 36,  pag. 474-481
Highly Efficient Neural Conversion of Human Pluripotent Stem Cells in Adherent and Animal-Free Conditions
D. LUKOVIC, A. LLORET, P. STOJKOVIC, D. RODRIGUEZ-MARTINEZ, M. ARAGO, F. RODRIGUEZ-JIMENEZ, P. GONZALEZ-RODRIGUEZ, J. LOPEZ-BARNEO, E. SYKOVA, P. JENDELOVA, J. KOSTIC, V. MORENO-MANZANO, M. STOJKOVIC, S. BHATTACHARYA and S. ERCEG
Stem Cells Translational Medicine, 2017 Apr,  Vol. 6,  pag. 1217-1226
hiPSC Disease Modeling of Rare Hereditary Cerebellar Ataxias: Opportunities and Future Challenges
D. LUKOVIC, V. MORENO-MANZANO, F. RODRIGUEZ-JIMENEZ, A. VILCHES, E. SYKOVA, P. JENDELOVA, M. STOJKOVIC and S. ERCEG
NEUROSCIENTIST, 2017 Oct,  Vol. 23,  pag. 554-566
Human iPSC derived disease model of MERTK-associated retinitis pigmentosa
D. LUKOVIC, A. CASTRO, A. DELGADO, M. BERNAL, N. PELAEZ, A. LLORET, R. ESPEJO, K. KAMENAROVA, L. SANCHEZ, N. CUENCA, M. CORTON, A. FERNANDEZ, A. SORKIO, H. SKOTTMAN, C. AYUSO, S. ERCEG VUKICEVIC and S. BHATTACHARYA
Scientific Reports, 2015 Aug,  Vol. 5,  pag. 12910
Brief Report: Astrogliosis Promotes Functional Recovery of Completely Transected Spinal Cord Following Transplantation of hESC-Derived Oligodendrocyte and Motoneuron Progenitors
D. LUKOVIC, L. VALDES-SANCHEZ, I. SANCHEZ-VERA, V. MORENO-MANZANO, M. STOJKOVIC, S. BHATTACHARYA and S. ERCEG
STEM CELLS, 2014 Feb,  Vol. 32,  pag. 594-599